Reach Us +1-218-451-2974


Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention | OMICS International | Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention

Aaron Carman1, Sarah Kishinevsky1, John Koren III1, Wenjie Lou2 and Gabriela Chiosis1*

1Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA

2Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA

Corresponding Author:
Gabriela Chiosis
Department of Molecular Pharmacology and Chemistry
Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
E-mail: [email protected]

Received date: March 22, 2013; Accepted date: April 08, 2013; Published date: April 24, 2013

Citation: Carman A, Kishinevsky S, John Koren III, Lou W, Chiosis G (2013) Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J Alzheimers Dis Parkinsonism S10:007. doi:10.4172/2161-0460.S10-007

Copyright: © 2013 Carman A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Maintenance of cellular homeostasis is regulated by the molecular chaperones. Under pathogenic conditions, aberrant proteins are triaged by the chaperone network. These aberrant proteins, known as “clients,” have major roles in the pathogenesis of numerous neurological disorders, including tau in Alzheimer’s disease, α-synuclein and LRRK2 in Parkinson’s disease, SOD-1, TDP-43 and FUS in amyotrophic lateral sclerosis, and polyQexpanded proteins such as huntingtin in Huntington’s disease. Recent work has demonstrated that the use of chemical compounds which inhibit the activity of molecular chaperones subsequently alter the fate of aberrant clients. Inhibition of Hsp90 and Hsc70, two major molecular chaperones, has led to a greater understanding of how chaperone triage decisions are made and how perturbing the chaperone system can promote clearance of these pathogenic clients. Described here are major pathways and components of several prominent neurological disorders. Also discussed is how treatment with chaperone inhibitors, predominately Hsp90 inhibitors which are selective for a diseased state, can relieve the burden of aberrant client signaling in these neurological disorders.